Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06283043
Other study ID # 2022/3749
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date March 5, 2024

Study information

Verified date February 2024
Source Inonu University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Our study was planned to analyze motor function, endurance and sleep attention information in Parkinson's patients with detailed and objective measurements.


Description:

Parkinson's Disease (PD) is a neurodegenerative disease that occurs with the loss of dopaminergic neurons in the basal ganglia (BG) and subsequently affects multiple brain regions. There are studies that evaluate executive functions rather than cognitive functions in Parkinson's patients. However, objective evaluations of the attention parameter are quite rare. Accordingly, our study was planned to examine the effects of motor function, depression and sleep on attention in Parkinson's patients with detailed and objective measurements. Parkinson's patients (n=27) and healthy controls (n=27) aged between 40-85 will be included in the study. Balance evaluation of the individuals participating in the study was carried out by functional reaching test, one-leg standing test and Berg balance scale; Endurance with a 30-second sit-and-stand test; reaction time; with mobile application; muscle strength by hand dynamometer; functional mobility with time up and go test; walking speed, with 10 m walk test; attention with the P300 device; depression, with the Beck depression scale; Sleep quality will be assessed with the Pittsburg sleep questionnaire. At the end of the study, the effects of motor functions, sleep and depression on attention will be examined and compared with healthy controls.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 54
Est. completion date March 5, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Being 1,2 or 3 according to the Hoehn and yahr scale - Being between the ages of 40-85 - Being diagnosed with Parkinson's according to UPDS - Being able to read and write - Being able to walk independently - Agreeing to participate in the study after providing detailed information about the research. - Mini mental test>24 Exclusion Criteria: - Having severe hearing/visual impairment-loss - Having an orthopedic, neurological or metabolic disease that may interfere with working - Having deep brain stimulation applied - Those with advanced cognitive impairment - Individuals with dementia - Patients taking anticholinergic, antidepressive or anxiolytic medications that may affect cognition, and those with other medical or neurological causes that may cause cognitive effects.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Inonu University Malatya Battalgazi

Sponsors (1)

Lead Sponsor Collaborator
Inonu University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary TUG functional mobility second, day 1, Values over 12 seconds indicate the risk of falling
Primary 10 m walking test walking speed second, day 1, lower results indicate better values, higher results indicate worse results
Primary 30 sec sit-stand test endurance again,day 1, higher results indicate better values, lower results indicate worse results
Primary berg balance test balance score, day 1, The score is between 0-56. A high total score indicates a good result
Primary one leg stance test balance second, day 1, higher results indicate better values, lower results indicate worse results
Primary functional reach test balance centimeter, day 1, higher results indicate better values, lower results indicate worse results
Primary hand dinamometer strenght kilogram, day 1, higher results indicate better values, lower results indicate worse results
Primary mobil application reaction time second, day 1, lower results indicate better values, higher results indicate worse results
Primary Pittsburg Sleep Quality Index sleep score, day 1, The score is between 0-21. A high total score indicates a bad result.
Primary Beck Depression depression score,day 1, The total score is between 0-63. A high total score indicates that the result is bad.
Primary P300 attention second, day 1, lower results indicate better values, higher results indicate worse results
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT04704349 - Latest Imaging SPECT System Evaluation Phase 1 N/A
Recruiting NCT03649503 - The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China
Completed NCT01385592 - Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT05608915 - External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait N/A
Recruiting NCT04871464 - Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease Phase 4
Withdrawn NCT04847609 - GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
Recruiting NCT05356845 - Oral Health, Orofacial Function and Oral Health Care in Patients With Parkinson's Disease
Completed NCT02021903 - Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies N/A
Completed NCT03065192 - Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease Phase 1
Not yet recruiting NCT04727658 - Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL) Phase 2
Recruiting NCT02696603 - Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) N/A
Completed NCT01491932 - Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Not yet recruiting NCT05818189 - Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing N/A
Recruiting NCT05906719 - Machine Vision Based MDS-UPDRS III Machine Rating
Completed NCT03156647 - Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome
Recruiting NCT02994719 - Gait Analysis in Neurological Disease
Completed NCT04974034 - Movement Disorders Analysis Using a Deep Learning Approach
Terminated NCT00686699 - Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) Phase 2
Completed NCT04925622 - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders